Talk to your researcher/doctor and have them explain the difference between
Galectin-1, useful for stem cells and Galectin-3.
http://www.medpagetoday.com/Cardiology/CHF/34513
Galectin-3 (Gal-3), a marker of cardiac fibrosis, is associated with
an increased risk of heart failure and death, researchers found.
Over a mean follow-up of nearly 9 years, those with elevated levels of Gal-3 had a significant 28% (95% CI 1.14 to 1.43,
P
.
"This collective experimental evidence suggests that Gal-3 may play a causal in cardiac remodeling," the authors stated.
However, adding Gal-3 to clinical factors resulted in only minor
improvements in net reclassification. It also did not substantially
increase the C-statistic (0.855 to 0.859).
Nonetheless, this is the first time that it's been shown that Gal-3
has a relationship with future heart failure, noted David Morrow, MD,
MPH, and Michelle O'Donoghue, MD, MPH, of Brigham and Women's Hospital
in Boston, in an accompanying editorial.
Although Gal-3 has been associated with adverse events in those with
heart failure, it has not been evaluated as a predictor of incident
heart failure in apparently healthy people.
Cardiac fibrosis, of which Gal-3 is a marker, plays an important role
in the development of heart failure. Earlier identification of elevated
levels of this betagalactoside-binding lectin might offer the
opportunity to treat people long before heart failure develops,
researchers said.
To fill in the gap, Levy and colleagues evaluated 3,353 participants
enrolled in the offspring cohort of the community-based Framingham Heart
Study.
The mean age of participants was 59 and 53% of them were women.
Overall, Gal-3 levels were higher in women than men (median 14.3 ng/mL
versus 13.1 ng/mL,
P<0 .05=".05" p="p">
Also, those with higher concentrations of the protein tended to be
older and have more cardiovascular risk factors such as high blood
pressure, diabetes, previous coronary artery disease, a higher body mass
index, and a lower estimated glomerular filtration rate (eGFR;
P less than 0.0001, for the trend for all).
When researchers performed a multivariate analysis, only eGFR was
dropped from the list of risk factors above, while B-type natriuretic
peptide (BNP) was added.
Examining the echocardiographic data, researchers found Gal-3 was
significantly associated with positive left ventricular remodeling.
Having higher levels of the protein conferred twice the odds of having
elevated left ventricular mass, they wrote.
But Gal-3 was not associated with fractional shortening, left ventricular systolic dysfunction, or left atrial size.
Crude heart failure rates progressed in a step-wise fashion with increasing Gal-3 quartiles.
During a mean follow-up period of 8.1 years, 5.1% of patients experienced first heart failure events.
The upper limits for Gal-3 quartiles for men and women were 15.4
ng/ml to 47.7 ng/ml and 16.8 ng/ml to 52.1 ng/ml, respectively. The
lower limits were 3.9 ng/ml to 11.1 ng/ml for men and 5.0 ng/ml to 12.0
ng/ml for women.
Among the 25% of people with the highest Gal-3 levels, the annual
rate of heart failure was 12 per 1,000 person-years compared with 3 per
1,000 person-years for the 25% of participants with the lowest levels.
Researchers added BNP to the multivariate analysis and found that
high Gal-3 levels increased the risk of a first heart failure incident
by a significant 23%. However, BNP was associated with a significant 46%
increased risk.
There was no difference regarding Gal-3 levels between those with preserved ejection fraction and depressed ejection fraction.
Levy and colleagues suggested that directly modulating that Gal-3
pathway may be beneficial in these patients. They called for more study
into how assessment of Gal-3 can help this patient population.
Morrow and O'Donoghue noted that Gal-3 is also sensitive to fibrotic
conditions in other areas such as the liver, lungs, and kidneys. For
that reason, it may difficult to include the protein in a screening
strategy.
Study limitations included the modest number of heart failure events
and the possibility that Gal-3 levels are influenced by other
conditions. Also, the results may not be generalizable because patients
were mostly Caucasian.
0>
Rest at the link.